| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/03/2005 | US20050026985 Such as N-{5-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide; useful for the treatment of mammalian infertility |
| 02/03/2005 | US20050026981 Stable oral solid drug composition |
| 02/03/2005 | US20050026980 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of autoimmune diseases |
| 02/03/2005 | US20050026975 Such as ethyl 4-chloroacetamido-N-(3,4-dichlorobenzyl)indole-2-carboxylate use in the treatment of disease mediated by monocyte chemoattractant protein-1 |
| 02/03/2005 | US20050026972 Benzimidazol-or indol-aminoacetonitrile derivatives for parasite control |
| 02/03/2005 | US20050026967 Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases |
| 02/03/2005 | US20050026963 Pyrazole substituted directly, or by a bridge, with a heteroaryl group containing N adjacent to the point of connection of the heteroaryl useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, bipolar disorder, circadian rhythm and sleep disorders |
| 02/03/2005 | US20050026956 Carbinols for the treatment of neuropathic dysfunction |
| 02/03/2005 | US20050026942 Chemokine receptor binding heterocyclic compounds |
| 02/03/2005 | US20050026941 preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase used for prophylaxis of erectile dysfunction and cardiovascular disorders |
| 02/03/2005 | US20050026936 1,4-Dideoxy-1-C-(4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino-D-ribitol derivatives or salts; parasite purine nucleoside, -hydrolase, -phosphorylase and/or phosphoribosyl transferase inhibitors; antiprotozoa, anticarcinogenic, antiinflammatory, and immunosuppressant agents; autoimmune diseases |
| 02/03/2005 | US20050026932 Adenosine A2a receptor antagonists |
| 02/03/2005 | US20050026931 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| 02/03/2005 | US20050026927 Pyrazole derivatives as psychopharmaceuticals |
| 02/03/2005 | US20050026915 As melanin concentrating hormone (MCH)receptor antagonists, for prevention or treatment of obesity or eating disorders; (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide |
| 02/03/2005 | US20050026904 Cathepsin S, K, F, L and B reversible inhibitory amidino and guanidino peptidyl compounds useful for treating autoimmune diseases, rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis |
| 02/03/2005 | US20050026901 Antihistaminic spiro compounds |
| 02/03/2005 | US20050026895 Having a superior acetylcholinesterase inhibitory action; treatment of Alzheimer's disease, brain disorders, attention deficit disorders; side effect reduction |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026865 Feeds contains alginate and an acceptable carriers; nutrients; weight gain |
| 02/03/2005 | US20050026846 Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism |
| 02/03/2005 | US20050026840 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics |
| 02/03/2005 | US20050026831 inhibitors of notch signalling comprising proteins or polypeptides having notch ligand domains, multimeric proteins or polynucleotide codes for the protein or polypeptides, used in the treatment of cancer; vaccines |
| 02/03/2005 | US20050026289 Virus clearance of neoplastic cells from mixed cellular compositions |
| 02/03/2005 | US20050026283 Using electric field modification to transfer components across cell barriers; organelle transfer; in vitro fertility |
| 02/03/2005 | US20050026278 RNA interference mediating small RNA molecules |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026226 Serum Paraoxonase |
| 02/03/2005 | US20050026220 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/03/2005 | US20050026211 Compositions and methods relating to lung specific genes |
| 02/03/2005 | US20050026182 Human CDNAS and proteins and uses thereof |
| 02/03/2005 | US20050025821 Lipid-comprising drug delivery complexes and methods for their production |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025774 Such as N-(2-ethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; for preventing, treating or delaying AIDS |
| 02/03/2005 | US20050025767 Contains antibody binding to macrophage migration inhibitory factor |
| 02/03/2005 | US20050025760 Pemphigus monoclonal antibody |
| 02/03/2005 | US20050025757 Oxygen carrier system, artificial oxygen carrier, and reducing agent |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | DE10329955A1 Verwendung eines hydroalkoholischen Extrakts aus Bauhinia zur Herstellung einer Zubereitung Use of a hydroalcoholic extract of Bauhinia for producing a preparation |
| 02/03/2005 | DE10057976B4 Verfahren zur Herstellung von Pektinhydrolyseprodukten A process for producing pectin hydrolysis products |
| 02/03/2005 | CA2533494A1 Aryl heteroaromatic products, compositions comprising the same and use thereof |
| 02/03/2005 | CA2532397A1 (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-l-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| 02/02/2005 | EP1502962A2 Methods for assessing and treating cancer |
| 02/02/2005 | EP1502916A1 Piperidine derivatives having ccr3 antagonism |
| 02/02/2005 | EP1502603A1 DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM |
| 02/02/2005 | EP1502600A1 Use of botulinum toxin for treating smooth muscle disorders |
| 02/02/2005 | EP1502599A1 Active antiangiogenic therapy |
| 02/02/2005 | EP1502576A2 Composition containing a 2-thioacetamide and use thereof for stimulating growth or preventing fall out of keratin fibres |
| 02/02/2005 | EP1502109A2 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1) |
| 02/02/2005 | EP1501936A2 Cytokine protein family |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501923A2 Pak5-related compositions and methods |
| 02/02/2005 | EP1501919A1 Soya cell strains with high isoflavone content |
| 02/02/2005 | EP1501866A2 Apo-2 ligand variants and uses thereof |
| 02/02/2005 | EP1501862A2 Novel analogues of glucose-dependent insulinotropic polypeptide |
| 02/02/2005 | EP1501859A1 17a-FLUOROALKYL-11BETA-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS |
| 02/02/2005 | EP1501857A2 Novel pancortin-pablo protein interactions and methods of use thereof |
| 02/02/2005 | EP1501852A2 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 02/02/2005 | EP1501846A1 Tricyclic macrolide antibacterial compounds |
| 02/02/2005 | EP1501841A2 Non nucleoside reverse transcriptase inhibitors |
| 02/02/2005 | EP1501837A1 Cascade esters of camptothecins and methods of treating cancer using these compounds |
| 02/02/2005 | EP1501836A1 Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501827A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| 02/02/2005 | EP1501826A2 Substituted indoles as alpha-1 agonists |
| 02/02/2005 | EP1501825A2 Substituted imidazolylmethyl pyridine and pyrazine derivatives: gaba a receptor ligands |
| 02/02/2005 | EP1501819A1 Estrogen receptor modulators |
| 02/02/2005 | EP1501817A1 Imidazolinylmethyl aralkylsulfonamides |
| 02/02/2005 | EP1501813A2 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 02/02/2005 | EP1501809A1 Triazole derivatives as tachykinin receptor antagonists |
| 02/02/2005 | EP1501808A1 Tachykinin receptor antagonists |
| 02/02/2005 | EP1501807A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists |
| 02/02/2005 | EP1501804A1 Isoquinoline derivatives mao-b inhibitors |
| 02/02/2005 | EP1501803A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 02/02/2005 | EP1501797A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors |
| 02/02/2005 | EP1501796A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors |
| 02/02/2005 | EP1501794A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| 02/02/2005 | EP1501790A2 Novel sodium channel blockers |
| 02/02/2005 | EP1501605A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 02/02/2005 | EP1501547A1 Methods and conpositions for treating, preventing or delaying onset of a neoplasm |
| 02/02/2005 | EP1501539A1 Method for control of depression using c terminal growth hormone (gh) fragment |
| 02/02/2005 | EP1501538A2 Use of alpha-s2 casein precursor-derived peptides |
| 02/02/2005 | EP1501526A1 Curcumin for the prevention and/or treatment of tissue damage |
| 02/02/2005 | EP1501525A1 Method for producing preparations rich in tocotrienol |
| 02/02/2005 | EP1501524A2 Internal image antibodies for optical imaging and therapy |
| 02/02/2005 | EP1501515A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501514A2 Protein kinase modulators and methods of use |
| 02/02/2005 | EP1501513A2 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 02/02/2005 | EP1501511A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway |
| 02/02/2005 | EP1501508A1 Inhibitors of histone deacetylase |
| 02/02/2005 | EP1501505A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -t riazole for the treatment of autoimmune diseases |
| 02/02/2005 | EP1501497A2 Catechin multimers as therapeutic drug delivery agents |
| 02/02/2005 | EP1501488A1 USE OF GABA sb B /sb RECEPTOR POSITIVE MODULATORS IN GASTRO-INSTESTINAL DISORDERS |
| 02/02/2005 | EP1501467A2 Heterocyclo inhibitors of potassium channel function |
| 02/02/2005 | EP1501359A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| 02/02/2005 | EP1440161A4 7118, a human arginine n-methyltransferase family member and uses therefor |
| 02/02/2005 | EP1436382A4 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 02/02/2005 | EP1379257A4 Prodrugs of anticancer agents employing substituted aromatic acids |
| 02/02/2005 | EP1373267B1 Non-nucleoside reverse transcriptase inhibitors |
| 02/02/2005 | EP1351980A4 Peptides for activation and inhibition of delta pkc |